ResearcherTufts Medical CenterNo recent work listed

Lynne A. Lamb

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5009027229. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper

Papers 2

Pancreatic Adenocarcinoma Complicated by Sinistral Portal Hypertension. Last author DOI 10.7759/cureus.689 ↗
First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00280-013-2359-7 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Kristin Kaley · 2 shared papers, 2014–2016 · strength 0.14
- Paper Pancreatic Adenocarcinoma Complicated by Sinistral Portal Hypertension. DOI 10.7759/cureus.689 ↗
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗
Muhammad Wasif Saif · 2 shared papers, 2014–2016 · strength 0.14
- Paper Pancreatic Adenocarcinoma Complicated by Sinistral Portal Hypertension. DOI 10.7759/cureus.689 ↗
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗
Yung‐Chi Cheng · 1 shared paper, 2014 · strength 0.04
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗
Jia Li · 1 shared paper, 2014 · strength 0.04
- Paper First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients … DOI 10.1007/s00280-013-2359-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.